Edward Smith III has been in the pharmaceutical and medical device industry for over 30 years, and has more than 20 years of experience leading Regulatory Affairs at several companies. He most recently served as Senior Vice President of Regulatory Affairs & Quality Assurance at Conatus Pharmaceuticals Inc., from 2016 to 2019. Previously, from 2007 to 2016, he was the head of Regulatory Affairs and Quality Assurance at Zogenix Inc., leading the successful approval of the Sumavel DosePro and Zohydro ER new drug applications (NDAs). At Connetics, he managed the approval of 3 NDAs for dermatology indications, and previously he was the head of Regulatory Affairs at Nektar Therapeutics, Valeant Pharmaceuticals, and Radiance Medical Systems, Inc., working with drug, device, and drug/device combination products. He has successfully led efforts for U.S. Food and Drug Administration fast track designation, and orphan drug designation and approvals in the US and EU.
Dr. Smith started his career in cardiovascular R&D, having held positions at Mallinckrodt, Inc., serving as R&D team leader of the endovascular and cardiology divisions; at SmithKline Beecham Pharmaceuticals where he was part of the team that discovered and developed Carvedilol for congestive heart failure and hypertension; and at Ciba-Geigy Pharmaceuticals, Inc.
Dr. Smith has authored over 95 peer-reviewed scientific articles. He was a postdoctoral fellow at the Medical University of South Carolina and the Institute of Pharmacology, University of Cologne in West Germany. Dr. Smith received his MBA at Washington University, and his PhD in Physiology at Thomas Jefferson University. He graduated from Montana State University with a BS in Biology.